Loading clinical trials...
Loading clinical trials...
A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalating Study to Examine the Safety and Tolerability of Multiple Doses of KD025 (Formerly Called SLX-2119) in Healthy Male and Post- Menopausal Female Subjects
Conditions
Interventions
Belumosudil mesylate
Placebo
Locations
1
United States
Investigational site
Buffalo, New York, United States
Start Date
November 21, 2013
Primary Completion Date
March 6, 2014
Completion Date
March 6, 2014
Last Updated
June 26, 2023
Lead Sponsor
Kadmon, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions